Oncology Trials

Research & Education > TriHealth Hatton Research Institute
oncology trials

The TriHealth Hatton Research Institute's Oncology research team, and researchers at  TriHealth’s Cancer Institute and Mary Jo Cropper Family Center for Breast Care conduct important clinical trials targeting improvements in the prevention and treatment of specific kinds of cancer. Composed of a team of research nurses and clinical research assistants, the TriHealth Hatton Research Institute's Oncology research team has many decades of experience in oncology research.

Clinical trials supported by our Oncology research team include cooperative group trials sponsored by the National Cancer Institute, studies through the Catholic Health Initiative, and Pharmaceutical Trials. 

Selected trials:

What is a Clinical Trial?

A clinical trial (also called “clinical research,” “research study,” and “protocol”) is a research study that evaluates a new test, drug or treatment in people to make sure it is safe and effective. Carefully conducted clinical trials are vital to discovering new, better, safer treatments for people, and improve health and quality of life.

Clinical trials are important today for many reasons, including:

  • Contributing to improved scientific knowledge about cancer: how to detect it, and how to treat it, and even how to prevent it
  • Possibly benefiting individual patients by providing newer and better treatments, and possibly, a cure 

More Information

For additional basic information about clinical trials:

Clinical Oncology Trials

Oncology: Molecular Profiling

 

EAY131: Molecular Analysis for Therapy Choice (MATCH).
Learn more.

Principal Investigator and Contact information:
Andrew Parchman, MD
513 853 1300

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
pam_daniel@trihealth.com

Diann Fischesser, RN
513 862 1892
diann_fischesser@trihealth.com

Angela Hein, RN
513 853 2252
angela_hein@trihealth.com

S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors.
Learn more.

Principal Investigator and Contact information:
Jack Basil, MD
513 853 1300

Study Coordinator and Contact information:
Diann Fischesser, RN
513 862 1892
diann_fischesser@trihealth.com  

Oncology: Breast

 

A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (BWEL Study). Learn more.

Principal Investigator and Contact information:
Barbara Wexelman, MD
513 853 1300

Study Coordinator and Contact information:
Heather Bibee, BS
513 862 3505
Heather_Bibee@trihealth.com

D3614C00001: A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC). Learn more.

Principal Investigator and Contact information:
Apruva Mehta, MD
513 853 1300

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
Pam_Daniel@trihealth.com

EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemo-therapy vs. Observation in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy.   Learn more.

Principal Investigator and Contact information:
Apurva Mehta, MD                
513 853 1300

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
pam_daniel@trihealth.com  

FLEX: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles.  Learn more.

Principal Investigator and Contact information:
Apurva Mehta, MD                
513 853 1300

Study Coordinator and Contact information:
Angela Hein, RN
513 853 2252
angela_hein@trihealth.com  

NRG BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed By Weekly Paclitaxel With Or Without Carboplatin For Node-Positive Or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer. Learn more.

Principal Investigator and Contact information:
Apurva Mehta, MD
513 853 1300

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
pam_daniel@trihealth.com  

NRG CC004: Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer Learn more.

Principal Investigator and Contact information:
James Pavelka, MD
513 853 1300

Study Coordinator and Contact information:
Pam Daniel, RN
513 865 5228
pam_daniel@trihealth.com  

NSABP B51/RTOG 1304:  A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy. Learn more.

Principal Investigator and Contact information: 
Corey Hobbs, MD                 
513 853 1300

Study Coordinator and Contact information: 
Angela Hein, RN
513 853 2252                    
angela_hein@trihealth.com  

S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy. Learn more.

Principal Investigator and Contact information:
Apruva Mehta, MD
513 853 1300

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
Pam_daniel@trihealth.com

WF 97116: A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment. Learn more.

Principal Investigator and Contact information:
Amie Jackson, MD
513 853 1300

Study Coordinator and Contact information:
Angela Hein, BSN, RN
513 853 2252
Angela_Hein@trihealth.com

Oncology: Gastrointestinal

 

A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair. Learn more.

Principal Investigator and Contact information:
David Draper, MD
513 853 1300

Study Coordinator and Contact information:
Barb Nye, BSN, RN
513 865 5914
Barbara_Nye@trihealth.com

EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer. Learn more.

Principal Investigator and Contact information:
David Draper, MD
513 853 1300

Study Coordinator and Contact information: 
Barb Nye, BSN, RN
513 865 5914
Barbara_Nye@trihealth.com  

NRG-GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer. Learn more.

Principal Investigator and Contact information:
Corey Hobbs, MD
513 853 1300

Study Coordinator and Contact information: 
Barb Nye, BSN, RN
513 865 5914
Barbara_Nye@trihealth.com  

Oncology: Genitourinary

EA8143: A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC). Learn more.

Principal Investigator and Contact information:
Kirubel Tefera, MD
513 853 1300

Study Coordinator and Contact information: 
Barb Nye, BSN, RN
513 865 5914
Barbara_Nye@trihealth.com  

S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nabpaclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. Learn More.

Principal Investigator and Contact information:
Kirubel Tefera, MD
513 853 1300

Study Coordinator and Contact information:
Angela Hein, BSN, RN
513 853 2252
Angela_Hein@trihealth.com

AREN1721: A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups. Learn More

Principal Investigator and Contact information:
Kirubel Tefera, MD
513 853 1300

Study Coordinator and Contact information:
Stephanie Powers, BS
513 862 1650
Stephanie_Powers@trihealth.com

Oncology: Gynecology

 

GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus.  Learn more.

Principal Investigator and Contact information: 
James Pavelka, MD
513 853 1300

Study Coordinator and Contact information: 
Diann Fischesser, RN
513 862 1892
diann_fischesser@trihealth.com  

NRG GY005: A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS). Learn more                   .

Principal Investigator and Contact information:
James Pavelka, MD
513 853 1300

Study Coordinator and Contact information:
Diann Fischesser, RN
513 862 1892
diann_fischesser@trihealth.com  

NRG GY009: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer.  Learn more.

Principal Investigator and Contact information:
James Pavelka, MD
513 853 1300

Study Coordinator and Contact information:
Diann Fischesser, RN
513 862 1892
diann_fischesser@trihealth.com

NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer. Learn more.

Principal Investigator and Contact information:
James Pavelka, MD
513 853 1300

Study Coordinator and Contact information:
Stephanie Powers, BS
513 862 1650
stephanie_powers@trihealth.com

NRG CC004: Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer Learn more .

Principal Investigator and Contact information:
James Pavelka, MD
513 853 1300

Study Coordinator and Contact information:
Diann Fischesser, RN
513 862 1892
diann_fischesser@trihealth.com  

LCCC 1326: Metformin with the Levonorgestrel-Releasing Intrauterine Device for the treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients. Learn more.

Principal Investigator and Contact information:
Kevin Schuler, MD
513 853 1300

Study Coordinator and Contact information:
Diann Fischesser, RN
513 862 1892
diann_fischesser@trihealth.com  

OPTEC: Ohio Prevention and Treatment of Endometrial Cancer (OPTEC) Initiative: Universal Screening for DNA Mismatch Repair Deficiency and Personalized Cancer Treatment. Learn More.

Principal Investigator and Contact information:
Robert Neff, MD
513 853 1300

Study Coordinator and Contact information:
Stephanie Powers, BS
513 862 1650
stephanie_powers@trihealth.com 

Oncology: Hematology

 

C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6). Learn more.

Principal Investigator and Contact information: 
Saulius Girnius, MD
513 853 1300

Study Coordinator and Contact information:
Barb Nye, BSN, RN
513 865 5914
Barbara_Nye@trihealth.com

TAK-079-1002: An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy. Learn More.

Principal Investigator and Contact information:
Saulius Girnius, MD
513 853 1300

Study Coordinator and Contact information:
Barb Nye, BSN, RN
513 865 5914
Barbara_Nye@trihealth.com

Oncology: Lung Cancer

 

A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST): A screening trial for A081105 and E4512. Learn more.

Principal Investigator and Contact information: 
Andrew Parchman, MD
513 853 1300

Study Coordinator and Contact information:
Heather Bibee, BS
513 862 3505
Heather_Bibee@trihealth.com

A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo In Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC). An ALCHEMIST Treatment Trial.  Learn more.

Principal Investigator and Contact information: 
Andrew Parchman, MD
513 853 1300

Study Coordinator and Contact information:
Heather Bibee, BS
513 862 3505
Heather_Bibee@trihealth.com

CA209-77T: A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer. Learn More.

Principal Investigator and Contact information:
Andrew Parchman, MD
513 853 1300

Study Coordinator and Contact information:
Pam Daniel
513 865 5228
pam_daniel@trihealth.com

E4512: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations. An ALCHEMIST Treatment Trial. Learn more.  

Principal Investigator and Contact information: 
Andrew Parchman, MD
513 853 1300

Study Coordinator and Contact information:
Heather Bibee, BS
513 862 3505
Heather_Bibee@trihealth.com

LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study). Learn more.  

Principal Investigator and Contact information: 
Andrew Parchman, MD
513 853 1300

Study Coordinator and Contact information:
Heather Bibee, BS
513 862 3505
Heather_Bibee@trihealth.com

Oncology: Melanoma/Skin

 

20130193: A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® (Talimogene Laherparepvec) in Clinical Practice to Characterize the Risk of Herpetic Infection Among Patients, Close Contacts, and Health Care Providers; and Long-term Safety in Treated Patients. Learn more.

Principal Investigator and Contact information:
David Lee, MD
513 853 1300

Study Coordinator and Contact information:
Heather Bibee, BS
513 862 3505
Heather_Bibee@trihealth.com

Amgen ISS 20177504: Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor: A Pilot Study. Learn more.

Principal Investigator and Contact information:
David Lee, MD
513 853 1300

Study Coordinator and Contact information:
Angela Hein, RN
513 853 2252
angela_hein@trihealth.com

Oncology: Sarcoma

 

We are physicians, hospitals and communities working together to help you live better.